Valeritas’ V-Go helps type 2 diabetes control blood sugar levels in proof-of-concept study – Valeritas Holdings, Inc. (OTCMKTS:VLRX)

[ad_1]

Data from a proof-of-concept research confirmed kind 2 diabetics utilizing Valeritas Holdings’ (OTCQB:VLRX) V-Go Wearable Basal plus Bolus Insulin Delivery Device with a simplified physician-driven insulin titration algorithm improved their A1C management whereas lowering their insulin necessities. The outcomes can be introduced right this moment on the 17th Annual Diabetes Technology Meeting in Bethesda, MD.

15 sufferers had been evaluated after utilizing V-Go for 4 months. Most insulin changes had been made in the course of the first three weeks. 67% (n=10/15) achieved a mean A1C discount of 1.6% and a mean lower in every day insulin from 144U/day to 60U/day.

The incidence of hypoglycemia (low blood sugar) decreased from 23% at baseline to 7% by month four.

SeekingAlpha



[ad_2]
Source hyperlink

Leave a Reply

Your email address will not be published.